Johnson & Johnson
This article was originally published in The Tan Sheet
McNeil Consumer fourth quarter worldwide growth of 19% was "primarily the result" of the buyout of Merck's equity stake in the European nonprescription pharmaceutical business, J&J reports. Inspired by strong performance from Splenda, McNeil is "continuing to look at models and new opportunities to broaden that whole nutritional area, so we've got a whole organization looking at it" reports J&J CEO William Weldon. "We do feel there's a big opportunity, especially with the needs of childhood obesity and other things that are out there today." J&J global fourth quarter sales increased 13.3% to $12.8 bil...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.